EMA Authorised: Imatinib Accord (imatinib) — Accord Healthcare S.L.U.

View source ↗

Summary

The EMA authorised Imatinib Accord (imatinib) for several indications, including Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dermatofibrosarcoma, Myelodyspl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatofibrosarcoma
• Hypereosinophilic Syndrome
• Leukemia Myelogenous Chronic Bcr-abl Positive
• Myelodysplastic Myeloproliferative Diseases
• Precursor Cell Lymphoblastic Leukemia-lymphoma

Drugs mentioned

• Imatinib Accord (imatinib)

Snippet

Status: Authorised. Therapeutic area: Precursor Cell Lymphoblastic Leukemia-Lymphoma;Dermatofibrosarcoma;Myelodysplastic-Myeloproliferative Diseases;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Hypereosinophilic Syndrome. MAH: Accord Healthcare S.L.U.. Decision date: 05/05/2025